News | January 31, 2022
Granules Pharmaceuticals concludes USFDA audit with three minor observations
The audit is a PAI for two of its product applications filed from this facility
The audit is a PAI for two of its product applications filed from this facility
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
The company has been manufacturing masks since the Covid-19 outbreak in 2020
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Previously, the use of the drug was limited to patients requiring hospitalization
Go-ahead for pivotal clinical trial which is expected to commence by March
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
